| Prev Close | 302.86 |
| Open | 303.04 |
| Day Low/High | 299.71 / 304.68 |
| 52 Wk Low/High | 215.78 / 374.99 |
| Volume | 895.56K |
| Avg Volume | 1.97M |
Biogen Inc. (BIIB)
302.60
0.26
0.09
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 163.19M |
| Market Cap | 49.19B |
| EPS | 31.50 |
| P/E Ratio | 9.32 |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: A Recession Might Be Good Medicine Right Now
A bear market, if it gets us all to slow down, may be necessary to slow the coronavirus' spread -- but this doesn't mean I'm giving up. To the contrary.
Sangamo Therapeutics Shows Promise
Let's check out the charts of SGMO and come up with a trading strategy.
Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon
It's no secret that the Fed would like to get out of the short-term repo business.
4 Favorite Biotech Stock Picks for 2020
The Medical Technology Stock Letter's top pick rose 357% in 2019.
Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average
Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.
Jim Cramer: Think Owning Tech Is Hard? Look at This Post-Impeachment Record
A lot of the names that fell hard after the Clinton impeachment have been record earners since then.
Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not
We're seeing lots of companies snapping up their peers, and the market is applauding.
Real Money Post Industrial Average Exits October on Top
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
Jim Cramer: Nothing's Changed, Except the Prices
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Big Biotech Receives Some Needed Shots in the Arm
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
Jim Cramer: The Soundness of My Methods
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
We Have a Market That Has Become a Little Extended
This looks like a normal pause within an uptrend.
Biogen Stock Soars on Alzheimer's Drug News
BIIB also reported third quarter results Tuesday that easily beat the consensus both on the top and the bottom line.
China Trade Optimism, Do Boeing's Numbers Matter? Trading Apple: Market Recon
There is a chance that Presidents Trump and Xi sign something when they meet up at the APEC summit this November in Santiago, Chile.
No Shortage of Candidates for the Next Portfolio of Losers
Dozens of beaten-up stocks could see tax-loss selling into the end of the year; here's a preview of some that could make up the next Tax Loss Selling Portfolio.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
5 Favorites for Biotech Stock Buyers
For those with a long-term horizon, here are some top picks.
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Big Pharma Sees Pockets of Recent Insider Buying
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
3 Trends Driving This Earnings Season
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
High Flyers and Low Flyers
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
Now at the Plate, Your Pinch Hitter, Bret Jensen
I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...
